Of the 151 (46.6%) patients who were not included in the study, 90 (27.8%) were excluded because they did not present baseline ALT and/or AST measurements and, 61 (18.2%) were considered lost to follow up since they failed to return to the service in order to measure their AST and/or ALT levels within 30 and/or 60 days after initiating treatment for TB (Fig 1). This evidence concerns the gene GPT and tuberculosis.